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AbsTrACT
Objectives cOViD-19 has rapidly become a major 
health emergency worldwide. Patients with iBD are at 
increased risk of infection, especially when they have 
active disease and are taking immunosuppressive 
therapy. The characteristics and outcomes of cOViD-19 
in patients with iBD remain unclear.
Design This italian prospective observational cohort 
study enrolled consecutive patients with an established 
iBD diagnosis and confirmed cOViD-19. Data regarding 
age, sex, iBD (type, treatments and clinical activity), 
other comorbidities (charlson comorbidity index (cci)), 
signs and symptoms of cOViD-19 and therapies were 
compared with cOViD-19 outcomes (pneumonia, 
hospitalisation, respiratory therapy and death).
results Between 11 and 29 March 2020, 79 patients 
with iBD with cOViD-19 were enrolled at 24 iBD referral 
units. Thirty- six patients had cOViD-19- related pneumonia 
(46%), 22 (28%) were hospitalised, 7 (9%) required 
non- mechanical ventilation, 9 (11%) required continuous 
positive airway pressure therapy, 2 (3%) had endotracheal 
intubation and 6 (8%) died. Four patients (6%) were 
diagnosed with cOViD-19 while they were being 
hospitalised for a severe flare of iBD. age over 65 years 
(p=0.03), Uc diagnosis (p=0.03), iBD activity (p=0.003) 
and a cci score >1 (p=0.04) were significantly associated 
with cOViD-19 pneumonia, whereas concomitant iBD 
treatments were not. age over 65 years (p=0.002), active 
iBD (p=0.02) and higher cci score were significantly 
associated with cOViD-19- related death.
Conclusions active iBD, old age and comorbidities 
were associated with a negative cOViD-19 outcome, 
whereas iBD treatments were not. Preventing acute iBD 
flares may avoid fatal cOViD-19 in patients with iBD. 
Further research is needed.
bACkgrOunD
COVID-19 is an infectious respiratory syndrome 
with a wide spectrum of presentations and 
outcomes.1 2 It is caused by a new virus called 
severe acute respiratory syndrome coronavirus 2 
(SARS- CoV-2) that was first identified in Wuhan, 
China, but has now spread worldwide. COVID-19 
has rapidly become a major health emergency 
that has evolved into a pandemic. On 30 January 
2020, the WHO Director- General declared that 
the outbreak of this viral infection constitutes a 
Public Health Emergency of International Concern. 
SARS- CoV-2, and a few other highly pathogenic 
coronaviruses, pose a global threat to public 
health,2 3 but the risk of severe disease and death is 
greater in elderly subjects and in those with comor-
bidities.4 5
significance of this study
What is already known on this subject?
 ► COVID-19 has rapidly become a major health 
emergency worldwide, resulting in >1.7 million 
persons infected with 6% lethality.
 ► Patients with IBD are at increased risk of 
infection, especially when they have active 
disease and are taking immunosuppressive 
therapy.
 ► The characteristics and outcomes of COVID-19 
in patients with IBD remain unclear.
What are the new findings?
 ► Active IBD, older age and presence of 
comorbidities have been found to be associated 
with a higher risk of COVID-19 pneumonia and 
death in patients with IBD.
 ► Concomitant therapy with biologics and 
immunosuppressants did not associate with 
worse COVID-19 prognosis in patients with IBD.
How might it impact on clinical practice in the 
foreseeable future?
 ► This is the first report on the characteristics and 
outcomes of COVID-19 in patients with IBD.
 ► Maintaining effective therapy to avoid disease 
flares in patients with IBD may reduce the risk 
of fatal COVID-19.
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Table 1 Baseline characteristics of patients with IBD with COVID-19
Overall (n=79) CD (n=32) uC (n=47)
Age, years, median (range) 45 (18–80) 39 (18–73) 51 (23–80)
Female, n (%) 35 (44.3%) 15 (46%) 20 (43%)
Active disease, n (%) 22 (28%) 4 (12%) 18 (35%)
Concomitant therapy for IBD, n (%)
  None 5 (6%) 5 (16%) 0 (0%)
  Aminosalicylates 24 (30%) 3 (9%) 21 (45%)
  Thiopurines 6 (8%) 1 (3%) 5 (11%)
  Systemic corticosteroids 9 (11%) 1 (3%) 8 (17%)
  Calcineurin inhibitors 1 (1%) 1 (3%) 0 (0%)
  Anti- TNF 29 (37%) 15 (47%) 14 (30%)
  Vedolizumab 15 (20%) 5 (16%) 10 (21%)
  Ustekinumab 3 (4%) 3 (9%) 0 (0%)
  Investigational drugs (within a 
clinical trial)
2 (2%) 2 (6%) 1 (2%)
  Pregnancy,n (%) 1 (1%) 0 (0%) 1 (2%)
  Comorbidities,n (%) 30 (38%) 10 (31%) 20 (43%)
Charlson Comorbidity Index, n (%)
  0 43 (54%) 21 (66%) 22 (47%)
  1 14 (18%) 7 (22%) 7 (15%)
  2 12 (15%) 3 (9%) 9 (20%)
  3 6 (8%) 1 (3%) 5 (11%)
  4 3 (4%) 0 (0%) 3 (6%)
  5 1 (1%) 0 (0%) 1 (2%)
Type of comorbidity, n (%)
  None 49 (62%) 22 (68%) 27 (57%)
  Essential hypertension 9 (11%) 2 (6%) 7 (14%)
  Coronary heart disease 5 (6%) 0 (0%) 5 (10%)
  COPD 5 (6%) 0 (0%) 4 (8%)
  CMV colitis 2 (3%) 0 (0%) 2 (4%)
  Psoriasis 2 (3%) 2 (6%) 0 (0%)
  Ankylosing spondylitis 2 (3%) 2 (6%) 0 (0%)
  Rheumatoid arthritis 1 (1%) 1 (3%) 0 (0%)
  Multiple sclerosis 1 (1%) 0 (0%) 1 (2%)
  Undifferentiated connective tissue 
disease
1 (1%) 1 (3%) 0 (0%)
  Hypothyroidism 1 (1%) 0 (0%) 1 (2%)
  Kaposi’s sarcoma 1 (1%) 0 (0%) 1 (2%)
COVID-19- related symptoms, n (%)
  None 2 (3%) 1 (3%) 1 (3%)
  Fever 71 (90%) 28 (88%) 43 (91%)
  Cough 52 (66%) 19 (59%) 33 (70%)
  Dysosmia or dysgeusia 19 (24%) 10 (31%) 9 (19%)
  Arthralgia or myalgia 18 (23%) 10 (31%) 8 (17%)
  Dyspnoea 15 (19%) 8 (25%) 7 (15%)
  Diarrhoea 12 (15%) 5 (16%) 7 (15%)
  Rhino- pharyngitis 13 (16%) 8 (26%) 5 (10%)
  Dysphonia 1 (1%) 1 (1%) 0 (0%)
  Conjunctivitis 1 (1%) 1 (1%) 0 (0%)
CD, Crohn’s disease; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease.
Patients with IBD are generally at increased infectious risk, 
especially when being treated with steroids, immunosuppres-
sants or biologics.6 The nature and magnitude of this risk vary 
with the type of immunosuppressive drug and with the patient’s 
sex and age. Immunosuppressant therapy increases the risk of 
opportunistic viral infections,7 although one study found that 
the use of antitumour necrosis factor (TNF)- alpha appears to 
reduce the risk of opportunistic viral infections.8 Preliminary 
data from China9 and Italy10 suggest that the incidence of severe 
forms of COVID-19 in patients with IBD could be lower than 
in the general population. The first reports of COVID-19 in 
patients with IBD with fatal outcomes are starting to emerge.11
So far, the risk, presentation and severity of coronavirus infec-
tion in patients with IBD have not been studied. This study aimed 
to describe how COVID-19 presents and evolves in patients with 
IBD, and to identify risk factors that predict the severity and 
outcomes of COVID-19 in patients with IBD.
MeTHODs
This was a prospective, observational cohort study initiated and 
supported by the Italian Group for the Study of Inflammatory 
Bowel Disease (IG- IBD). All centres affiliated with IG- IBD were 
invited to participate in the study with an open call for partici-
pation sent in the first week of March 2020. Patient enrolment 
started on 11 March 2020.
Patients were eligible if they were adults who had an estab-
lished diagnosis of Crohn’s disease (CD) or UC for at least 6 
months and who also had an either confirmed or likely diagnosis 
of COVID-19. A confirmed diagnosis of COVID-19 was defined 
as the PCR- confirmed presence of SARS- CoV-2 genome in a 
nasopharyngeal swab. A likely diagnosis was made in patients 
who did not undergo viral testing if they had a history of contact 
with an infected person, together with at least three of the 
following signs and symptoms: fever, cough, dyspnoea, dysosmia 
and dysgeusia, or CT findings of COVID-19 lung infection.12 13 
For all eligible patients, we collected the following data from 
medical charts: age, sex, IBD type, IBD treatments, IBD clin-
ical activity (defined as a partial Mayo score ≥3 with a rectal 
bleeding subscore ≥1 for UC,14 15 and a Harvey- Bradshaw Index 
for CD ≥516), other comorbidities (expressed with Charlson 
Comorbidity Index (CCI)17), signs and symptoms of COVID-19 
(fever, cough, dyspnoea, dysosmia/dysgeusia, pharyngitis, diar-
rhoea, arthralgia- myalgia/asthenia, rhinitis, dysphonia), thera-
pies for COVID-19 and COVID-19 outcomes. These data were 
entered into an electronic database accessible to participating 
centres.
The primary objective was to describe the characteristics of 
COVID-19 in patients with IBD in terms of negative outcomes, 
such as the development of COVID-19- related pneumonia 
(demonstrated by chest CT or radiography), hospitalisation, 
respiratory therapy and death. The secondary objective was to 
investigate possible associations between baseline characteristics 
of patients with IBD and negative COVID-19 outcomes.
sTATIsTICAl AnAlyses
Because the incidence and prevalence of COVID-19 in the IBD 
population is not known, sample size was not calculated. Differ-
ences between subgroups of patients were tested for significance 
using Fisher’s exact test. Associations among categorical vari-
ables were assessed for significance using the χ2 test or Fisher's 
exact test, and logistic regression. A value of p<0.05 was consid-
ered to be statistically significant.
resulTs
Between 11 and 29 March 2020, we enrolled 79 consecutive 
patients with IBD with diagnosis of COVID-19. The patients 
were in treatment at one of 24 Italian IBD referral units for 
either CD (n=32) or UC (n=47). Overall, 49 patients had 
COVID-19 confirmed by a positive nasopharyngeal swab, 
while 30 cases were confirmed by clinical and radiological 
signs. Baseline characteristics of the patients are shown in 
table 1.
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Figure 1 Negative outcomes of COVID-19 in the overall IBD cohort, 
and for patients with Crohn’s disease (CD) and UC. CPAP, continuous 
positive airway pressure.
Table 2 Association between potential risk factors and COVID-19- 
related pneumonia
risk factor Or 95% CI P value
Age >65 years 5.87 1.15 to 29.66 0.03
CCI score >1 2.91 1.06 to 9.21 0.04
UC diagnosis 2.72 1.06 to 6.99 0.03
Active IBD 10.25 2.11 to 49.73 0.003
Corticosteroids 4.94 0.95 to 25.55 0.05
Thiopurines 1.21 0.22 to 6.40 0.82
Anti- TNF 1.18 0.47 to 2.97 0.71
Vedolizumab 0.53 0.16 to 1.73 0.29
Bold indicates p < 0.05.
CCI, Charlson Comorbidity Index; TNF, tumour necrosis factor.
Overall population analysis
The most common COVID-19 symptoms were fever (90%), 
cough (66%), dysosmia/dysgeusia (24%), arthralgia/myalgia 
(23%), dyspnoea (19%), diarrhoea (15%) and rhino- pharyngitis 
(16%). Overall, 36 patients (46%) had COVID-19- related 
pneumonia, 22 (28%) were hospitalised, 7 (9%) required non- 
mechanical ventilation, 9 (11%) required continuous positive 
airway pressure (CPAP) therapy, 2 (3%) underwent endotracheal 
intubation and 6 (8%) died (figure 1). No significant differ-
ences between patients with CD and UC were found in terms 
of concomitant medications: steroids (p=0.13), thiopurines 
(p=0.52), anti- TNF (p=0.11) and vedolizumab (p=0.71). Three 
patients with CD were under treatment with ustekinumab, but 
no patient with UC was taking this drug because it is not reim-
bursed for patients with UC in Italy. The one patient taking 
both infliximab and azathioprine did not have pneumonia. 
One patient under triple immunosuppression (steroids+azathi-
oprine+infliximab), who had a concomitant cytomegalovirus 
(CMV) infection and was hospitalised at the time of COVID-19 
diagnosis, developed pneumonia but had full recovery.
Four patients (6%) were diagnosed with COVID-19 while 
they were being hospitalised for a severe flare of IBD. No signif-
icant differences were found between patients with UC and CD 
in terms of disease activity (p=0.13).
At least one comorbidity was present in 30 patients with 
IBD (38%). In the overall population, 9 (11%) had essential 
hypertension, 5 (6%) had coronary heart disease (CHD), and 5 
(6%) had chronic obstructive pulmonary disease. Two patients 
with UC had CMV- related colitis (3%) treated with anti-
viral therapy. Eight patients (10%) had concomitant immune- 
mediated diseases (two psoriasis, two ankylosing spondylitis, 
one rheumatoid arthritis, one multiple sclerosis, one undiffer-
entiated connective tissue disease and one hypothyroidism). The 
frequency of immune- mediated disease was significantly greater 
in patients with CD than UC (7 vs 1, p=0.02). One patient had 
concomitant Kaposi’s sarcoma.
COVID-19 pneumonia
Among the 36 patients with pneumonia, 26 (72%) had UC and 
10 had CD; altogether, 13 (36%) had active IBD. At the time of 
diagnosis, 18 (50%) were under treatment with 5- aminosalicylic 
acid, 7 (19%) were on steroids, 3 (8%) on thiopurines, 14 (39%) 
on anti- TNF, 5 (14%) on vedolizumab, 1 (3%) on ciclosporin 
and 1 on (3%) filgotinib as an experimental drug within a clinical 
trial. No patient was receiving ustekinumab. Fifteen patients had 
at least one comorbidity (19% systemic hypertension, 11% CHD 
and 5% immune- mediated diseases). All four patients who were 
hospitalised for an acute severe IBD flare developed COVID-19 
pneumonia during the hospitalisation period.
A significant association was found between the risk of 
COVID-19 pneumonia and age over 65 years (p=0.03), 
UC diagnosis (p=0.03), moderate- to- severe disease activity 
(p=0.02), any disease activity (p=0.003) and a CCI score 
>1 (p=0.04) (online supplementary figure 1 and table 2). In 
contrast, concomitant IBD treatments were not associated with 
the risk of COVID-19 pneumonia. After adjustment for concom-
itant steroid use, active disease remained significantly associated 
with the risk of COVID-19 pneumonia (p=0.01).
COVID-19 pneumonia required hospitalisation in 22 patients 
(61%), 16 patients required subintensive respiratory assistance 
(non- mechanical ventilation or CPAP therapy, 44%), 2 patients 
(6%) required endotracheal intubation and 6 (16%) patients 
died. Hospitalisation and the need for respiratory assistance 
were significantly more frequent in patients with active IBD 
(both p<0.001). No association was found between concomi-
tant IBD treatments and the need for hospitalisation or respira-
tory therapies for COVID-19 pneumonia.
COVID-19-related deaths
COVID-19 led to death in six patients (five men). The patients’ 
median age was 73 years (range 53–80 years; four were over 65 
years of age). Half of the patients had active IBD, two were being 
hospitalised for a severe IBD flare at the time of COVID-19 diag-
nosis, and five had UC. Three cases had concomitant hyperten-
sion, and three had CHD; all had a CCI score >0 and four had 
a score >2 (online supplementary figure 1). Regarding concom-
itant IBD treatments, three patients were taking 5- aminosalicylic 
acid, two systemic steroids and one anti- TNF therapy. All these 
patients received respiratory therapy: five had subintensive treat-
ment (mechanical ventilation or CPAP), and two had endotra-
cheal intubation before death.
Age over 65 years (p=0.002), active IBD (p=0.02), moderate- 
to- severe active disease (p=0.005) and higher CCI score were 
significantly associated with COVID-19- related death in our 
IBD cohort (table 3). When adjusted for steroid use, moderate- 
to- severe disease remained significantly associated with COVID-
19- related death (p=0.02).
DIsCussIOn
The COVID-19 pandemic is a challenge for healthcare systems 
worldwide. Italy has been the first European country affected 
by the pandemic since 20 February 2020. Since then, as of 10 
April 2020, according to preliminary data released by the Italian 
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Table 3 Association between potential risk factors and COVID-19- 
related death
risk factor Or 95% CI P value
Age >65 years 19.6 2.95 to 130.6 0.002
CCI score >1 16.66 1.80 to 153.9 0.01
Active IBD 8.45 1.26 to 56.56 0.02
UC diagnosis 2.95 0.31 to 27.73 0.34
Corticosteroids 6.28 0.89 to 44.24 0.064
Anti- TNF 0.40 0.04 to 3.78 0.42
CCI, Charlson Comorbidity Index; TNF, tumour necrosis factor.
Ministry of Health and the Italian Civil Protection, >140 000 cases 
have been confirmed, and >18 000 people have died; 30% of cases 
were reported in Lombardy region, and 69% in northern Italy.
The impact of COVID-19 on immune- mediated disease remains 
unknown, as does the risk of COVID-19- related complications 
and death. This is particularly true in patients with IBD who are 
frequently treated with immunosuppressive agents and who are at 
risk of serious opportunistic infections.6
We identified 79 patients with IBD who developed COVID-19 
since the beginning of the pandemic. This number is relatively small 
compared with the general population infected by SARS- COV-2 in 
Italy. The geographic distribution of our IBD population was in 
line with the general distribution of the confirmed cases in Italy, 
since 85% of our study population lives in northern Italy. These 
numbers suggest that patients with IBD are not at higher risk of 
being infected by the SARS- COV-2 than the general population.
Active IBD was found to associate with a negative COVID-19 
outcome (pneumonia, respiratory support, hospitalisation and 
death). All these patients had active disease before their COVID-19 
diagnosis and were under treatment for a disease flare. The 
majority of them had active UC with at least mild rectal bleeding. 
Therefore, although we cannot exclude that in some cases, diar-
rhoea was due to COVID-19,18 gastrointestinal symptoms were 
related mainly to IBD. A diagnosis of UC significantly associated 
with COVID-19 pneumonia, but not with death. Other factors 
significantly associated with worse outcomes were older age and 
higher CCI score, whereas numerically more men died in our 
cohort. Old age, comorbidities and male sex have also been found 
to be risk factors for lethality in the general Italian population.5 
These findings suggest that COVID-19 complications and lethality 
in patients with IBD reflect the natural history of COVID-19, and 
are apparently unrelated to the use of immunosuppressive therapy.
About 50% of patients with IBD who developed pneumonia, 
and 50% of patients who died, were not under any immunosup-
pressive therapy (such as systemic corticosteroids, thiopurines, 
small molecules and monoclonal antibodies). Whether to stop 
or continue immunosuppressive therapy in IBD is debated. The 
International Organization for the Study of Inflammatory Bowel 
Diseases (IOIBD) suggests to continue maintenance therapy, 
paying attention only to high doses of systemic corticosteroids 
(>20 mg/day prednisone or equivalent).19 Ping et al reported 
no case of COVID-19 among 318 patients with IBD in Wuhan, 
China, but they nonetheless stopped immunosuppressive therapy 
preventively.9 Our data show there was no increased risk of nega-
tive COVID-19 outcome related to the use of immunosuppressive 
drugs, while a trend towards statistical significance was observed 
for concomitant corticosteroid therapy. This find is concordant 
with IOIBD recommendations,19 but there is a significant risk of 
COVID-19 pneumonia and death in patients with active disease. 
Moreover, four patients with IBD who were hospitalised for a 
severe IBD flare developed COVID-19, which was fatal in two 
cases. Severe active disease requiring the use of steroids, especially 
in elderly patients, could be associated with worse outcomes, as 
recently reported.11 This finding highlights the need to continue 
effective maintenance therapy in order to avoid severe IBD flares, 
which would require hospital visits for testing or admission. Since 
hospitals may be the place with the highest risk of infection as long 
as the pandemic lasts, there is a consequent need to restructure IBD 
care and to replace hospital visits with virtual clinics and remote 
monitoring,20–22 whenever possible.
This study has several limitations. First, not all IBD cases were 
included because there is no national registry for patients with 
IBD in Italy. The identified patients were recruited mainly because 
they reported their COVID-19 diagnosis to their referral centre, 
they were hospitalised or they were in contact with their physician 
during a virtual visit. The relatively few patients, however, is in line 
with a report from Bergamo Hospital, where there were no cases 
of COVID-19 among patients with IBD, and no hospitalisations, in 
one of the most affected areas of northern Italy.10 Second, the diag-
nosis and tallying of COVID-19 cases in Italy differ from region to 
region, and may be underestimated or overestimated depending 
on the geographical provenience. We identified our patients with 
COVID-19 based on criteria of the Italian Ministry of Health,23 
but some patients may remain undiagnosed. Third, the study was 
limited to investigate risk factors related to IBD that might be less 
frequent. In this context, data from large, multicentre registries, 
such as the SECURE- IBD registry, may be helpful to confirm our 
findings.
COnClusIOn
This is the largest report on the characteristics and outcomes 
of COVID-19 in patients with IBD. Active disease, especially in 
elderly patients with comorbidities, was associated with nega-
tive COVID-19 outcomes, whereas IBD treatments were not. 
Preventing patients with IBD from being hospitalised for acute 
flares may be the best way to avoid fatal COVID-19 in this patient 
population. Larger studies with longer follow- up periods are 
needed to confirm these findings.
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